Biosante Pharmaceuticals (BPAX)
Biosante Pharmaceuticals Market Cap: 62.63M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BPAX Market Cap Rankings
| Overall | 17th percentile | 3833 of 4649 |
| Sector | 22nd percentile | 408 of 525 in Healthcare |
| Industry | 22nd percentile | 127 of 163 in Biotechnology |
BPAX Market Cap Range, Past 5 Years
| Minimum | 27.04M | Dec 2008 |
| Maximum | 257.40M | Jun 2011 |
| Average | 111.02M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these BPAX related companies
BPAX News
Anyone have insight on $bpax ? Is this another game the shorts are playing?
about 6 days ago by stock_sniper
about 6 days ago by stock_sniper
RT @HulkHogan Looks like it could be another monster volume day on $BPAX/over 4M traded in 1st half hour!
about 6 days ago by mainetrader
about 6 days ago by mainetrader
@randal $BPAX When are people going to learn that past performance does not predict future performance. You can't predict price by a chart
about 6 days ago by Flynt2012
about 6 days ago by Flynt2012
RT @MarkeScope: Top Winners last Monday, May 21, 2012
#NASDAQ :
$ZNWAZ,$BPAX,$BWOWW,$ROSG,$VIMC
#StockMarket #MarkeScope #invest #money
about 6 days ago by Bw1128
about 6 days ago by Bw1128
@adamfeuerstein $GALE do you think this piggy going back down below 1.20 today or is $BPAX a better short?
about 6 days ago by randal
about 6 days ago by randal
@BioDueDiligence and if $BPAX pops again tomorrow sir?? will it just be a miracle??? LOL
about 6 days ago by BiopharmaPro
about 6 days ago by BiopharmaPro
RT @ankitm514: $BPAX--56%+ today. WTF. Told you to hold. 1 have 500k shares.
about 6 days ago by HulkHogan
about 6 days ago by HulkHogan
$BPAX up 56% on no news?? The only thing I can think of is insider buying!!!!
about 6 days ago by BiopharmaPro
about 6 days ago by BiopharmaPro
$BPAX up 52%, vow longs deserve this runup as paid bashers have really created artificial negative sentiment here #WELLKNOWN BASHERS $$
about 6 days ago by peterumble
about 6 days ago by peterumble
$ROSG again effect of Obtaining Medicare Coverage of miRview mets2 Assay (Wed, May 16) thats big for tiny mkt cap co. $ARNA $BPAX
about 6 days ago by EPS_MomentuM
about 6 days ago by EPS_MomentuM
@mainetrader $BPAX wouldn't they have to reverse split to stay listed on the nasdaq???
about 6 days ago by BiopharmaPro
about 6 days ago by BiopharmaPro
$bpax hopefully most of the shorts are out. But if they get in again, watch out.
about 6 days ago by stock_sniper
about 6 days ago by stock_sniper
$BPAX still not getting involved before reverse split. Ya there is volume but the stock is under 50 cents. Looks like it is coming back down
about 6 days ago by jimmieB
about 6 days ago by jimmieB
Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates Biosante Pharmaceuticals, Inc. for Securities Fraud
May 09, 12:24PM Business Wire
May 09, 12:24PM Business Wire
Small Biotech Companies Look to Benefit From Shift to "First to File" Patent System
May 03, 8:20AM Marketwire
May 03, 8:20AM Marketwire
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
BioSante Pharmaceuticals, Inc. to Present at BioCentury Future Leaders in the Biotech Industry Conference
Apr 17, 7:55AM Business Wire
Apr 17, 7:55AM Business Wire
BioSante (BPAX) Reports Encouraging Data from Recent Pill-Plus Studies
Mar 20, 7:56AM Street Insider
Mar 20, 7:56AM Street Insider
BioSante Pharmaceuticals Announces Positive Pill-Plus™ Data Presentation
Mar 20, 7:55AM Business Wire
Mar 20, 7:55AM Business Wire
FAST Act to Modernize Approval Process -- Cardium and BioSante Poised to Benefit
Mar 19, 8:20AM Marketwire
Mar 19, 8:20AM Marketwire
BioSante Pharmaceuticals Reports Financial Results for 2011 and Corporate Highlights
Mar 13, 5:04PM Business Wire
Mar 13, 5:04PM Business Wire
BioSante Pharmaceuticals, Inc. to Present at Roth Health Care Conference
Mar 09, 7:55AM Business Wire
Mar 09, 7:55AM Business Wire
BioSante Pharma (BPAX) Reports Encouraging Data from GVAX in mCRPC Phase I w/ Escalated Dosage
Mar 05, 7:57AM Street Insider
Mar 05, 7:57AM Street Insider
BioSante’s Prostate Cancer Vaccine Resulted in Stable Disease in Over 50% of Patients in Newly Published Study
Mar 05, 7:55AM Business Wire
Mar 05, 7:55AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BPAX | 0.5183 | -0.00 | -0.25% | 62.63M |
| BP | 38.36 | +0.13 | +0.34% | 121.32B |
| BOXC | 25.90 | +0.49 | +1.93% | |
| BOX | 18.08 | -0.22 | -1.20% | 366.84M |
| BOSC | 0.7601 | -0.00 | -0.51% | 3.398M |
| BKBK | 8.12 | +0.00 | +0.00% | 17.38M |
| BK | 20.64 | -0.09 | -0.43% | 24.87B |
| BJZ | 16.68 | +0.00 | +0.01% | |
| BJRI | 44.56 | -0.13 | -0.29% | 1.244B |
| BJK | 31.62 | +0.06 | +0.19% |